Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mosapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mosapride SCHEMBL29400580 | 1.00 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6228981 | 1.00 | DRD3 (1.00) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6227991 | 0.99 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL2369236 | 0.99 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6225436 | 0.99 | DRD3 (0.98) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL5150929 | 0.98 | DRD3 (0.97) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL6229365 | 0.95 | DRD3 (0.91) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| SCHEMBL7364946 | 0.94 | KCNH2 (0.88) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| SCHEMBL8004478 | 0.93 | DRD3 (0.86) | DRD3MEN1LMNACYP1A2CYP3A4 | |
| Mosapride SCHEMBL258620 | 0.92 | DRD3 (0.85) | DRD3MEN1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3763 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| CN-120078838-A | Traditional Chinese medicine composition with function of improving spleen and stomach and preparation method thereof | 广州市康培健母婴用品有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119241462-A | Mosapride composition, preparation method and application thereof | 吉林修正药业新药开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118852048-A | Preparation method of mosapride | 吉林修正药业新药开发有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118652795-A | Bifidobacterium bifidum Bbifi-2 for reducing fat and improving glucose tolerance and application thereof | 四川厌氧生物科技有限责任公司 | 2024-09-17 | — | — | CN | claimed |
| CN-116211847-B | Application of saururus chinensis ketone in preparation of medicine for preventing and/or treating irritable bowel syndrome | 四川省医学科学院·四川省人民医院 | 2024-09-13 | — | — | CN | claimed |
| CN-118384299-A | Medical organism in-vivo endoscope positioning marking liquid and preparation and application thereof | 江苏德威兰医疗器械股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| US-6132771-A | USEFUL IN TREATMENT OF DISORDERS ASSOCIATED WITH GASTRO OESOPHAGEAL REFLUX DISEASES | ASTRAZENECA AB (SE) | 2000-10-17 | — | — | US | claimed |
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| CN-1183049-A | Oral Pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent | ASTRA AB (SE) | 1998-05-27 | — | — | CN | claimed |
| EP-0814840-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | Astra Aktiebolag (SE) | 1998-01-07 | — | — | EP | claimed |
| WO-1997025065-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | ASTRA AKTIEBOLAG (SE) | 1997-07-17 | — | — | WO | claimed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | claimed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | claimed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | claimed |